Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

I have been “inducing” few friends and family

Message Board Public Reply | Private Reply | Keep | Replies (3)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153968
(Total Views: 815)
Posted On: 04/06/2021 8:33:24 AM
Avatar
Posted By: TechGuru
I have been “inducing” few friends and family members to invest on CYDY in lieu of me investing even more (last purchase was after NP’s local TV station “three finger in front of camera waving” just before CD-12 results.

When the price goes up I am a hero and get invited to events and dinners … even get "out of the blue "good morning, how-are-you? calls” … when it goes down I get even more phone calls asking: when is it going to recover?? When should I sell ??? And social events and invitational call-ins diminish dramatically.

In any way. To the point: ” what do I tell everybody ??

The price will recover when we get an EUA (if we get one I as always say). But ... the price will go ballistic when we get a BTD in Oncology.

All bets are off then and this is what I am aiming at.

So … in order to keep my cool and explain to myself why I bought even more shares in the $4-$5 range (I am purposely not saying exactly where ) I continue reading Oncology-related information on the CCL5/CCR5 axis.

For those willing (or desperately needing) to do the same I recommend “The Inflammatory Chemokine CCL5 and Cancer Progression” by D. Aldinucci1 and A. Colombatti.

https://www.hindawi.com/journals/mi/2014/292376/

1367635847_ScreenHunter_704Apr.0608.30.jpg

This discusses several cancers and depicts the role of CCL/CCR5 in several hematological malignancies (multiple Myeloma, Hodgkin Lymphoma) and solid tumors: Breast, Melanoma, Gastric, Colon, Prostate, Ovarian.

For example, in respect to Breast Cancer:

Quote:
4.1. Breast Cancer. CCL5, while being minimally expressed by normal breast epithelial duct cells, is highly expressed by breast tumor cells at primary tumor sites, regional lymph nodes, and metastatic sites, indicating that CCL5 expression is acquired in the course of malignant transformation and that CCL5 plays a role in breast cancer development and/or progression. Increased positivity and expression levels of CCL5 by breast tumor cells are significantly associated with disease progression, relapse, and/or metastasis, compared to patients in remission. In this tumor the major source of CCL5 is the tumor cells ; however, CCL5 is also expressed by infiltrating leukocytes and mesenchymal stem cells (MSCs) of the tumor microenvironment. CCL5 is also present in interstitial fluids perfusing the tumor, in pleural effusions, and in serum. A functional CCR5 receptor is expressed by a subpopulation of human breast cancer cell lines and displays a functional response to CCL5. In addition, oncogene transformation induces CCR5 expression, and the subpopulation of cells that express a functional CCR5 also displays increased cell migration and invasiveness. A microarray analysis on 2,254 human breast cancer specimens found increased expression of CCL5 and its receptor CCR5, but not CCR3 , in the basal and HER-2 genetic subtypes. In contrast, when a similar analysis was performed in non-neoplastic breast samples, no correlation between CCL5 and CCR5 expression levels was found, indicating that CCL5/CCR5 signaling may be preferentially activated during the development of specific breast cancer subtypes. CCL5 expression is strongly associated with the progression of breast cancer, particularly the triple-negative breast cancer (TNBC), and may represent an immunotherapeutic target in the TNBC. Hypoxia is a major selective factor that promotes the growth of tumors with a diminished susceptibility to radiation and chemotherapy and is associated with cancer progression, cancer metastasis, and thus poor prognosis. Hypoxia induces a strong increase of both CCL5 and CCR5 expressions by breast cancer cells. Under this experimental condition CCL5 stimulates cell migration rather than cell proliferation and neutralization of CCL5 inhibits the hypoxia-induced migration of cancer cells. Similarly, overexpression of CCR5 increases cell migration, and knockdown of CCR5 attenuates hypoxia-mediated cell migration.



It goes on for the other types of cancer and goes on to depict how can the axis be interrupted.

Conclusion: we are in the right path and we should be granted a BTD pronto !!! The “prize” is huge in terms of patients worldwide and there is no money in thos word to pay for the benefits that will be brought-in if we can demonstrate clinical benefit.

We will


(27)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us